A process built around the one thing that actually determines a pharmaceutical project’s timeline: your review capacity, not our production speed.
Timeline is shaped more by your internal review capacity than by our production speed, since most pharma projects wait on medical, regulatory or brand sign-off between stages rather than on build time. A straightforward brochure site with a single reviewer can launch in weeks; a multilingual platform with multiple approval layers takes longer. See our full breakdown at how long does a pharma website take for the stages that typically set the pace.
We recommend whichever fits your situation, and that is not always a rebuild. If your existing platform can support the content structure, review workflow and integrations you need, we build within it and avoid unnecessary migration cost. When the platform is holding the project back through missing multilingual support, weak permissions or an unsupported stack, we recommend migration and explain the reasoning before you commit to it.
Yes, working alongside an internal marketing, IT or regulatory team is the normal way our projects run rather than the exception. We agree responsibilities and review checkpoints early so your team’s input lands before design decisions harden, not after. At handover we provide documentation and platform training so your team can operate and update the site independently, whether they were closely involved throughout the build or joined only at key milestones.
Yes, multilingual builds are a regular part of our pharma work across European markets. We structure content, translation workflow and regulatory review so each market’s approval sits on a shared framework instead of duplicating review overhead per language. See multilingual pharmaceutical websites for how we handle market-specific compliance requirements alongside a consistent core platform, and get in touch if your markets need different levels of localisation.
Scope changes get costed and scheduled as soon as they come up, rather than absorbed silently into the existing timeline. We assess the impact on the current phase, quote the additional work and agree a revised schedule with you before proceeding. This keeps changes visible and budgeted instead of becoming a source of dispute at delivery, and it applies whether the change comes from your side or from a regulatory requirement discovered mid-project.
As involved as you want. Some clients run regular reviews with us throughout the build, others prefer to see the platform at defined milestones — either way, documentation and platform ownership transfer at handover so your team isn’t locked out afterward.
Tell us your situation and we will tell you how this process would apply.